MEXICOR EFFECTIVENESS IN PATIENTS WITH CHRONIC HEART FAILURE AND METABOLIC SYNDROME
In total, the study included 60 45-64-year-old patients in early post-infarction phase, with chronic heart failure (CHF), Functional Class II-III, and metabolic syndrome (MS). The patients were randomised into two groups (n=30 in each group). In the main group, standard CHF therapy was extended by a...
Main Authors: | M. E. Statsenko, S. V. Turkina, E. D. Evtereva |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«FIRMA «SILICEA» LLC
2009-12-01
|
Series: | Российский кардиологический журнал |
Subjects: | |
Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1406 |
Similar Items
-
NEW POTENTIAL OF MEXICOR IN THE TREATMENT OF CHRONIC HEART FAILURE AMONG PATIENTS WITH METABOLIC SYNDROME
by: M. E. Statsenko, et al.
Published: (2010-12-01) -
MEXICOR IN THE COMBINATION THERAPY OF CHRONIC HEART FAILURE AND TYPE 2 DIABETES MELLITUS
by: M. E. Statsenko, et al.
Published: (2011-12-01) -
CARDIONATE IN COMBINED THERAPY OF ISCHEMIC CHRONIC HEART FAILURE AMONG PATIENTS WITH METABOLIC SYNDROME
by: M. E. Statsenko, et al.
Published: (2010-08-01) -
MEXICOR EFFECTIVENESS IN PATIENTS WITH BRADYARRHYTHMIAS
by: A. A. Kotlyarov, et al.
Published: (2009-06-01) -
EFFECTS OF MILDRONATE, AS A PART OF COMBINED HEART FAILURE THERAPY, ON CARBOHYDRATE AND LIPID METABOLISM AND OXIDATIVE STRESS PARAMETERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
by: M. E. Statsenko, et al.
Published: (2010-04-01)